Navigation Links
Alfacell Reports Financial Results for Third Quarter of Fiscal 2008

SOMERSET, N.J., June 9 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported its financial results for the third quarter of fiscal 2008.

The company recorded a net loss of approximately $5.0 million, or $0.11 per basic and diluted common share, for the third fiscal quarter ended April 30, compared to a net loss of approximately $2.0 million, or $0.04 per basic and diluted common share, for the third quarter of fiscal 2007. Research and development expenses increased by approximately $1.4 million during the third quarter of fiscal 2008 as compared to the same quarter a year ago primarily due to expenses incurred related to the company's preparations for the completion of its ONCONASE(R) rolling New Drug Application ("NDA") submission. Increased general and administrative expenses of approximately $1.5 million for the third quarter of fiscal 2008 were primarily the result of the accrual of compensation expense related to entering a retirement agreement with the company's CEO in April 2008.

Net loss for the nine-month period ended April 30, 2008 of approximately $9.4 million, or $0.20 per basic and diluted common share, represents an increase of approximately $3.1 million, compared to the $6.3 million net loss, or $0.14 per basic and diluted common share, for the same period in fiscal 2007.

Cash and Liquidity

As of April 30, the company had cash and cash equivalents of approximately $7.8 million, a decrease of approximately $2.4 million, compared to cash and cash equivalents of approximately $10.2 million on Jan. 31. The company believes that this level of liquidity is sufficient to support its activities into the fourth quarter of fiscal year 2009, based on current expectations for the planned completion of the ONCONASE rolling NDA. The company will be eligible to receive a minimum milestone payment of $20 million, up to a maximum of $30 million, from its U.S. partner, Strativa Pharmaceuticals, in the event that the NDA submission results in the company receiving marketing approval for ONCONASE.

Clinical Trials Update

Alfacell has completed patient enrollment in a confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from unresectable malignant mesothelioma (UMM) and reached the required number of evaluable events to conduct the formal statistical analyses required to complete the final sections of the ONCONASE rolling NDA. As the company has previously reported, the results of the preliminary statistical analysis of the data did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need. Based on the preliminary statistical analysis of the data, Alfacell will continue with the planned submission of the remaining components of the ONCONASE rolling NDA. The company plans to present the results of the trial at an upcoming scientific conference.

The company has completed enrollment in its Phase I clinical trials for patients suffering from non-small cell lung cancer (NSCLC) and other solid tumors and is now currently planning for the follow-on Phase II clinical trials.

"The completion of our fiscal third quarter marks the point where we have entered the most important phase for the commercialization of ONCONASE," said Lawrence A. Kenyon, Alfacell's president. "We are moving forward with the completion of our rolling NDA and appreciate the support expressed by our partners around the world for pursuing a U.S. approval for ONCONASE as a second-line treatment for malignant mesothelioma."

Conference Call & Webcast

Alfacell will host a conference call and Webcast to discuss the financial results at 11 a.m. EDT on Monday, June 9. To participate in the live conference call, U.S. residents may dial 1-877-407-9205, and international callers may dial 1-201-689-8054. A replay of the call will be available until June 16. To access the replay, U.S. residents may dial 1-877-660-6853, and international callers may dial 1-201-612-7415 and enter account number 286 and conference ID number 287301. A live Webcast and replay of the conference call will be available on Alfacell's Web site at


ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of Par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong, USP Pharma Spolka Z.O.O., an affiliate of US Pharmacia, for Eastern Europe, and GENESIS Pharma, S.A. for Southeastern Europe.

ONCONASE has been granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to a recently completed Phase IIIb study in malignant mesothelioma, Alfacell is currently planning for Phase II clinical trials in other oncology indications. For more information, visit

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.


Unaudited Condensed Statements of Operations

Three-Months Ended Nine-Months Ended

April 30 April 30

2008 2007 2008 2007

Revenues $--- $--- $--- $---


Research and

development 2,704,980 1,252,811 6,354,271 4,295,574

General and

administrative 2,386,992 856,892 5,032,243 2,844,673

Total expenses 5,091,972 2,109,703 11,386,514 7,140,247

Loss from operations (5,091,972) (2,109,703) (11,386,514) (7,140,247)

Interest income, net 65,833 82,142 191,146 303,968

State tax benefit --- --- 1,755,380 510,467

Net loss $(5,026,139) $(2,027,561) $(9,439,988) $(6,325,812)

Net loss per common

share -- basic and

diluted $(0.11) $(0.04) $(0.20) $(0.14)

Shares used in

computation of net

loss per share:

Basic and diluted 47,122,191 45,147,204 46,802,187 44,778,890

Unaudited Balance Sheet Data:

April 30, July 31,

2008 2007

Cash and cash equivalents $7,843,906 $6,968,172

Total assets $8,574,152 $7,820,499

Current liabilities $2,784,209 $1,829,900

Accumulated deficit $(101,511,743) $(92,071,755)

Total stockholders equity (deficiency) $(243,398) $5,778,480

Media Contact: Investor Contact:

David Schull or Wendy Lau Andreas Marathovouniotis

Russo Partners Russo Partners

212-845-4271 212-845-4235

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alfacell Announces Retirement of Chief Executive Officer
2. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
3. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
4. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
5. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
6. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
7. Alfacell to Present at BIO InvestorForum 2007
9. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
10. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
11. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
Post Your Comments:
(Date:10/10/2017)... ... October 10, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces a presentation by ... Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in North ... in Harvard University’s Departments of Physics and Astronomy, has been selected for membership in ... winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery of ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers ... perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ...
(Date:10/5/2017)... LINDA, CA (PRWEB) , ... October 05, 2017 , ... ... innovators, engineers, and scientists from around the world, is giving back to cancer research ... sold in October. , Now through October 31, shoppers can use promo code ...
Breaking Biology Technology:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates  ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market ... the next decade to reach approximately $14.21 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):